Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Peanut Allergy - Global Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com

May 9, 2019

DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Peanut Allergy - Market Insights, Epidemiology and Market Forecast - 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peanut Allergy from 2017 to 2028 segmented by seven major markets.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Peanut Allergy Epidemiology

According to the publisher, the prevalent population of Peanut Allergy was estimated to be 8,693,872 [7MM] in 2018. United States accounts for the highest Peanut Allergy cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Peanut Allergy, followed by Germany.

Peanut Allergy Management

Currently, there is no standard of care for patients with Peanut Allergy, highlighting a pressing need to develop safe and effective curative interventions. The primary care of treatment, include antihistamines and injectable epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. However all these therapies are used as off-label therapies and there is no approved therapy yet for the treatment of Peanut Allergy.

The primary care of treatment, include antihistamines and injectable epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. Antihistamines, known as H1 blockers, are beneficial for the treatment of acute mild reactions, (e.g., itching, sneezing, hives and rashes), although they cannot stop or control a severe reaction. Medications in this class include diphendydramine and cetirizine. Antihistamines do not treat anaphylaxis and have no life-saving capacity. Diphenhydramine has been commonly used as the antihistamine of choice for acute food allergic reactions given its prompt onset of action and ready availability, though epinephrine is still the first-line therapy for anaphylaxis.

Cetirizine is a second generation antihistamine with a similar onset but longer duration of action (=24 hours) compared to diphenhydramine. Furthermore, CNS effects are less commonly reported. Cetirizine has been used by patients in outpatient clinic for the treatment of acute allergic food reactions. In order to meet the high unmet need of Peanut Allergy treatment regimen, companies across the globe have shifted their focus towards this therapeutic area.

Recent studies show promise in the effectiveness and safety of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Additionally, improved diagnostic testing provides more accurate results while minimizing risk.

Peanut Allergy Market Outlook

The Peanut Allergy (PWS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the global market of Peanut Allergy (PWS) was estimated to be USD 3144.8 million in 2018. The United States accounts for the largest market size of Peanut Allergy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.

Peanut Allergy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The overall dynamics of Peanut Allergy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Aimmune Therapeutics’ AR101, DBV Technologies’ Viaskin Peanut, AnaptysBio’s ANB020 and Genentech’s Omalizumab. Out of these emerging therapies, AR101 (Aimmune Therapeutics) is expected to be launched in 2019 in the US. Aimmune’s AR101 is expected to grab maximum market share, as it is currently in Phase III stage of clinical development with very good safety and efficacy results, and will therefore influence the market size with a greater percentage. DBV Technologies’s Viaskin Peanut, although would be launched later than AR101, i.e. in 2020, but still is expected to provide a significant competition in the therapeutic market.

Peanut Allergy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Peanut Allergy Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Peanut Allergy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Peanut Allergy market.
  • Organize sales and marketing efforts by identifying the best opportunities for Peanut Allergy market.
  • To understand the future market competition in the Peanut Allergy market.

Companies Mentioned

  • Aimmune Therapeutics
  • DBV Technologies
  • AnaptysBio
  • Genentech

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/86c54g

View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005439/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/09/2019 06:17 AM/DISC: 05/09/2019 06:17 AM